CHRNB3 (Cholinergic Receptor Nicotinic Beta Subunit 3) encodes the β3 subunit of the neuronal nicotinic acetylcholine receptor (nAChR). CHRNB3 is primarily expressed in the central nervous system, particularly in brain regions associated with reward, attention, and motor control. Unlike muscle-type nAChRs, CHRNB3 participates in neuronal nAChRs that modulate neurotransmission and have been implicated in Parkinson's disease, Alzheimer's disease, and addiction.
CHRNB3 (Cholinergic Receptor Nicotinic Beta Subunit 3) encodes the β3 subunit of the neuronal nicotinic acetylcholine receptor (nAChR). CHRNB3 is primarily expressed in the central nervous system, particularly in brain regions associated with reward, attention, and motor control. Unlike muscle-type nAChRs, CHRNB3 participates in neuronal nAChRs that modulate neurotransmission and have been implicated in Parkinson's disease, Alzheimer's disease, and addiction.
Structure
Subunit Composition
CHRNB3 combines with α subunits to form functional neuronal nAChRs:
Common configurations: α4β3, α2β3, α6β3*
Pentameric structure: Five subunits arranged around a central ion channel
Assembly: Requires co-assembly with α subunits for surface expression
Postsynaptic effects: Direct neuronal depolarization
Neuromodulation: Slow, prolonged effects on circuit activity
Expression Pattern
In the brain, CHRNB3 is highly expressed in:
Striatum — Motor control and reward
Substantia nigra pars compacta — Dopaminergic neuron cell bodies
Ventral tegmental area — Reward pathway
Thalamus — Sensory relay
Hippocampus — Learning and memory[@maskos2020]
Role in Disease
Dopaminergic neuron protection
nAChRs on dopaminergic neurons can be neuroprotective. CHRNB3-containing receptors may modulate this effect[@quik2022]. Activation of CHRNB3-containing receptors:
Reduces excitotoxicity: Modulates glutamate receptor function
Microglial phenotype: Shifting from pro-inflammatory to neuroprotective state
Alzheimer's Disease
CHRNB3 is relevant to AD through[@liu2021]:
Cognitive function — CHRNB3 in hippocampus and cortex contributes to attention and memory. nAChRs are enriched in brain regions critical for learning and memory.
Cholinergic therapies — Understanding nAChR subtypes may improve targeted therapy. Current AD treatments (donepezil, rivastigmine) are non-selective nAChR agonists.
Neuronal survival — nAChR activation may provide neuroprotective effects through:
[Maskos U, et al. The nicotinic receptor beta2 subunit is required for long-term memory formation. Mol Brain. 2020](https://pubmed.ncbi.nlm.nih.gov/32066425/)
[Quik M, et al. Nicotinic receptor modulation as a therapeutic strategy in Parkinson's disease. CNS Drugs. 2022](https://pubmed.ncbi.nlm.nih.gov/35275369/)
[Bordia T, et al. Nicotinic receptors as therapeutic targets for Parkinson's disease. Biochem Pharmacol. 2017](https://pubmed.ncbi.nlm.nih.gov/28576464/)